Program
JNJ-89862175
A development code.
Its studies are led by Johnson & Johnson.
Furthest: phase 1, since Oct 30, 20251 company-led study, 1 open or runningNext primary completion: Dec 15, 2026 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Johnson & Johnson | 11 open or running | phase 1since Oct 30, 2025 | Oct 30, 2025 | Dec 15, 2026phase 1 · NCT07223125 |
- Named in Johnson & Johnson’s own pipeline as
JNJ-2175
, phase 1, as of Oct 13, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 30, 2025First study: phase 1 study in Advanced-stage Solid TumorsFirst studyNCT07223125 · 360 planned · United States, France, South Korea
Ahead
- Dec 15, 2026Primary completion: phase 1 study in Advanced-stage Solid TumorsNCT07223125
TargetBeta
“A Phase 1 Study of JNJ-89862175, an Ectonucleotide Pyrophosphatase/Phosphodiesterase Family Member 3 Antibody Drug Conjugate, for Advanced Solid Tumors”study text, read by Claude · the study
Other programs on ENPP3
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| Anti-ENPP3/Anti-CD3 Bispecific Antibody JNJ-87890387 | Johnson & Johnson | phase 1 | 1 |
| GTX-B001rule | granular-therapeutics-limited | phase 1 | 1 |
Studies
All 1 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07223125Advanced-stage Solid Tumors · United States, France, South Korea | 1 | Recruiting | Dec 15, 2026 | 360 |
How it is read
Names in the registry
- “JNJ-89862175”, 1 entry
Codes read as this program: JNJ89862175.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.